Skip to main content

Critical Care Reviews Newsletter

Newsletter 575  |  December 18th, 2022

Please support our work to share science

Please support CCR for the cost of a cup of coffee per month

Welcome to the 575th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are randomised controlled trials reporting the long-term outcomes of critically ill COVID-19 patients treated in the various domains of the REMAP-CAP platform trial & a Bayesian interpretation of the pediatric THAPCA-OH cardiac arrest trial; systematic reviews and meta analyses on extracorporeal cardiopulmonary resuscitation for cardiac arrest & noninvasive ventilation for acute respiratory failure in pediatric patients; and observational studies on timing of prone positioning during VV-ECMO for ARDS & intracranial pressure monitoring in aneurysmal subarachnoid hemorrhage.

There are also guidelines on aneurysmal subarachnoid haemorrhage & acute coronary syndrome in the older adults; narrative reviews on hemodynamic monitoring in cardiogenic shock & concomitant cardiac arrest and cardiogenic shock complicating myocardial infarction; editorials on a new open access policy for original research for the JAMA Network & cardiogenic shock; a commentary on critical illness subclasses; as well as correspondence on high-flow versus Venturi mask oxygen therapy to prevent re-intubation & target trial emulation

If you only have time to read one review article this week, try this one on severe community-acquired pneumonia.

As We Near the Year's End....

As we approach the end of 2022, please consider supporting Critical Care Reviews. We are not-for-profit and work to freely disseminate the latest critical care research and provide equity of access to core clinical information. You can do this for as little as the price of a cup of coffee per month or make a one-off donation. If you find this newsletter valuable, please value it.

I hope you find this newsletter useful.


Until next week

Rob